Abstract 442P
Background
The number of permanent colostomies performed for rectal cancer is decreasing as trans-anal excision has become the first-choice surgical approach. However, the types of support required for patients who undergo permanent colostomies according to their courses are not elucidated. This study aims to identify the types of support needed by elderly permanent colostomy patients by the postoperative months and investigated how these affected their quality of life.
Methods
This study was performed by a hypothesis testing approach using an anonymous self-administered questionnaire, which were left with the participants, and 335 members of A Ostomy Association were recruited to participate. The questionnaire had three components: 11 original items about care needed by individuals with colostomies, the Ostomate QOL Survey and the SF-12v2. Basic respondent characteristics were totaled by simple tabulation, and correlation and multiple regression analyses were performed to investigate how the number of postoperative months affected the support that the individuals with permanent colostomies wished for, and how the support they wished for affected QOL. The survey period was September 2017. This study was approved by the research ethics committee of the institution.
Results
Data from 137 participants of the mean age of 76.5 years were included in the analysis. The analysis on how support individuals felt needed with permanent colostomies affected their QOL resulted in significant correlations between “Factors related to daily life” , “Physical condition” (β=-.294, p=.011), “Activity” (β=-.267, p=.011) and “Mental and emotional condition” (β=-.410, p=.000). The multiple regression analysis on the support that individuals with permanent colostomies wanted and health-related QOL resulted in significant associations between “Factors related to daily life” and “Roles in daily life ((β=-.285, p=.014) ,(β=-.363, p=.001).
Conclusions
This study suggested that there were differences in the support that elderly with permanent colostomies wanted depending on the number of months or years passed since their colostomy surgery. Furthermore, it showed that the more they wished for care related to their daily life and health-related QOL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
JAPS Grant-in-Aid for Scientific Research(B):25293443.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract